Krystal Biotech, Inc.
General ticker "KRYS" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $4.7B (TTM average)
Krystal Biotech, Inc. follows the US Stock Market performance with the rate: 43.8%.
Estimated limits based on current volatility of 3.0%: low 279.83$, high 297.28$
Factors to consider:
- Total employees count: 275 as of 2024
- Top business risk factors: Dependence on VYJUVEK, Geopolitical risks, Strategic risks and growth management, Social media risks, Intellectual property risks
- Current price 29.7% above estimated high
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [134.64$, 231.99$]
- 2025-12-31 to 2026-12-31 estimated range: [126.02$, 219.78$]
Financial Metrics affecting the KRYS estimates:
- Negative: with PPE of 48.1 at the end of fiscal year the price was high
- Positive: Operating profit margin, % of 22.61 > 18.33
- Positive: Return on assets ratio (scaled to [-100,100]) of 7.79 > 6.04
- Positive: 0.04 < Operating cash flow per share per price, % of 2.70
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: Inventory ratio change, % of -3.75 <= -0.76
Short-term KRYS quotes
Long-term KRYS plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $50.70MM | $290.51MM |
| Operating Expenses | $145.20MM | $160.43MM | $224.82MM |
| Operating Income | $-145.20MM | $-109.73MM | $65.69MM |
| Non-Operating Income | $5.22MM | $122.62MM | $29.66MM |
| R&D Expense | $42.46MM | $46.43MM | $53.57MM |
| Income(Loss) | $-139.97MM | $12.90MM | $95.36MM |
| Taxes | $0.00MM | $1.97MM | $6.20MM |
| Profit(Loss)* | $-139.97MM | $10.93MM | $89.16MM |
| Stockholders Equity | $522.23MM | $778.64MM | $946.38MM |
| Inventory | $0.00MM | $6.99MM | $26.51MM |
| Assets | $558.45MM | $818.36MM | $1,055.84MM |
| Operating Cash Flow | $-100.57MM | $-88.80MM | $123.42MM |
| Capital expenditure | $52.98MM | $11.80MM | $4.24MM |
| Investing Cash Flow | $-114.08MM | $82.64MM | $-163.44MM |
| Financing Cash Flow | $35.35MM | $202.75MM | $27.01MM |
| Earnings Per Share** | $-5.49 | $0.40 | $3.12 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.